‘Treatment as prevention’ method can limit HIV transmission, perspective suggests

A perspective in PLOS Medicine suggests that people with HIV who achieve viral suppression with antiretroviral therapy can avoid sexual transmission of HIV without using condoms, a significant study that lends hope that the “treatment as prevention” method can stop the spread of the HIV infection.

“This research embodies the idea that what is undetectable is untransmissible -; the new paradigm of U=U,” said Jeanne Marrazzo, M.D., MPH, director of the University of Alabama at Birmingham Division of Infectious Diseases and lead author of the perspective. “This is great news for the study of HIV transmission and warrants further research as we continue to seek a way to control and arrest the HIV epidemic.”

Research shows that people who use TDF-FTC as a preventive measure can avoid HIV infection, a method that is becoming more popular in the United States and is increasingly being rolled out in countries with major HIV epidemics. This gives researchers hope that this prevention modality will yield long-term control in the spread of HIV, even where condom use rates are low.

However, while HIV transmission is unlikely when antiretroviral therapy sustains viral suppression, a new challenge is at hand: the increasing rate of sexually transmitted infections that are accompanying the decline in condom use. These STIs include chlamydia, gonorrhea and syphilis, and all have increased markedly, particularly among men.

Marrazzo stresses that the idea is to confront this reality and have a dialogue about what it means, and to discuss alignment of research and funding priorities to ensure that both HIV and STI rates decline. She explains that it is critical that progress is made to halt the spread of any and all sexually transmitted infections, in real-world settings, and there is a need to develop effective solutions to do so.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below